Conversely, for patients experiencing disease progression after initial use of lorlatinib, administering lorlatinib at doses exceeding 100 mg daily may fail to offer therapeutic benefits for ALK-rearranged NSCLC patients with CNS diseases, highlighting the complexity of managing CNS progression after third-generation TKI therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.